Get started
Author

José Ortega

Observed names: J. Ortega, Jose Ortega
ORCID: 0009-0007-7115-2537
Observed ORCID: 0009-0007-7115-2537
OpenAlex ID: A5028299526
WRN inhibition leads to its chromatin-associated degradation via the PIAS4-RNF4-p97/VCP axis
2024 · Fernando Rodríguez Pérez, Dean Natwick, et al. · Nature Communications · 22
Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors.
2025 · Mridula Annette George, Gary Schwartz, et al. · Journal of Clinical Oncology · 11
PDF
A deficiency screen of the 3rd chromosome for dominant modifiers of the Drosophila ER integral membrane protein, Jagunal
2023 · Gerson Ascencio, Matthew A de Cruz, et al. · G3 Genes Genomes Genetics · 1
Enfermedad de Rosai-Dorfman con presentación cutánea y ausencia de mutaciones BRAF-V600, KRAS y NRAS: ¿trastorno neoplásico o reactivo
2019 · Isidro Machado, Javier Alcacer Fernández-Coronado, et al. · Revista Española de Patología · 1
Abstract PS2-07-26: Clinical performance of Signatera Genome assay for predicting recurrence in patients with breast cancer
2026 · W. McHayleh, C. Scalise, et al. · Clinical Cancer Research
Demographics, socioeconomic, and treatment patterns for adenocarcinoma with cartilaginous and osseous metaplasia: A National Cancer Database analysis.
2025 · Jose Ortega, Jasmeet Khera, et al. · Journal of Clinical Oncology
Transcriptome (RNA next generation sequencing) for personalizing of cancer treatment: A correlation with previous clinical resistance.
2021 · Manuel Sureda, Joseba Rebollo, et al. · Journal of Clinical Oncology
DNA and RNA next generation sequencing for personalizing cancer treatment: A single-center experience.
2020 · Joseba Rebollo, Manuel Sureda, et al. · Journal of Clinical Oncology
1145 POSTER Drug Resistance Induced by Plasmatic Concentrations of Paclitaxel and Carboplatin in Cancer Cell Lines
2011 · R. Luque, J. Delgado, et al. · European Journal of Cancer
Works count: 9
Citation count: 35
H-index: 2
I10-index: 2
Year
Topic
Type